Details for Patent: 12,397,120
Which drugs does patent 12,397,120 protect, and when does it expire?
Patent 12,397,120 protects ELIGARD KIT and FENSOLVI KIT and is included in five NDAs.
This patent has thirty patent family members in twenty-five countries.
Summary for Patent: 12,397,120
| Title: | Systems and methods for mixing syringe valve assemblies |
| Abstract: | A syringe mixing system is provided for housing and mixing contents between at least two syringes. In some embodiments, a syringe coupler is provided that receives first and second syringes and includes a valve member that is convertible between a closed position and an open position. Retention systems for preventing or inhibiting removal of at least one syringe after use are also provided. |
| Inventor(s): | James Sherman, Casey Dean, Carl Hart, John Bingham, Hossam Aboudagher |
| Assignee: | Tolmar International Ltd |
| Application Number: | US18/399,077 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Delivery; Device; |
Drugs Protected by US Patent 12,397,120
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tolmar | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021343-001 | Jan 23, 2002 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED PROSTATIC CANCER | ⤷ Start Trial | ||||
| Tolmar | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021379-001 | Jul 24, 2002 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED PROSTATIC CANCER | ⤷ Start Trial | ||||
| Tolmar | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021488-001 | Feb 13, 2003 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED PROSTATIC CANCER | ⤷ Start Trial | ||||
| Tolmar | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021731-001 | Dec 14, 2004 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED PROSTATIC CANCER | ⤷ Start Trial | ||||
| Tolmar | FENSOLVI KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 213150-001 | May 1, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF PEDIATRIC PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,397,120
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 124487 | ⤷ Start Trial | |||
| Australia | 2021405417 | ⤷ Start Trial | |||
| Canada | 3205655 | ⤷ Start Trial | |||
| China | 116847900 | ⤷ Start Trial | |||
| Colombia | 2023009588 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
